Cargando…

ABI2‐mediated MEOX2/KLF4‐NANOG axis promotes liver cancer stem cell and drives tumour recurrence

Tumour recurrence and drug resistance in hepatocellular carcinoma remain challenging. Cancer stem cells (CSCs) are responsible for tumour initiation because of their stemness characteristics. CSCs accounting for drug resistance and tumour relapse are promising therapeutic targets. We report that Abe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiandi, Li, Huizi, Zhang, Bin, Xiong, Zhiyuan, Jin, Zhe, Chen, Jiaxi, Zheng, Yang, Zhu, Xiangnan, Zhang, Shuixing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Experimental Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825985/ https://www.ncbi.nlm.nih.gov/pubmed/36017822 http://dx.doi.org/10.1111/liv.15412

Ejemplares similares

Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance
por: Sun, Nannan, et al.
Publicado: (2021)

Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury
por: Arriazu, Elena, et al.
Publicado: (2017)

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity
por: Ruffolo, Luis I, et al.
Publicado: (2022)

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
por: Zhang, Xiang, et al.
Publicado: (2021)

CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism
por: Søndergaard, Jonas Nørskov, et al.
Publicado: (2022)

NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression
por: Latif, Muhammad Umair, et al.
Publicado: (2022)

MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells
por: Liu, Ningning, et al.
Publicado: (2022)

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
por: Rao, Jianhua, et al.
Publicado: (2022)

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
por: Zhang, Qi, et al.
Publicado: (2019)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma
por: Wang, Ji, et al.
Publicado: (2022)

Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma
por: Aoki, Shuichi, et al.
Publicado: (2022)

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
por: Ikenaga, Naoki, et al.
Publicado: (2017)

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
por: Garnelo, Marta, et al.
Publicado: (2017)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study
por: Zhang, Qi, et al.
Publicado: (2023)

Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids
por: Gao, Yanhang, et al.
Publicado: (2019)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

TGF-β2 silencing to target biliary-derived liver diseases
por: Dropmann, Anne, et al.
Publicado: (2020)

Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36
por: Rey, Esther, et al.
Publicado: (2020)

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
por: Perugorria, Maria J, et al.
Publicado: (2019)

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
por: Esparza-Baquer, Aitor, et al.
Publicado: (2021)

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication
por: Ho, Daniel W H, et al.
Publicado: (2017)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

Scoping review of clinical practice guidelines on the management of benign liver tumours
por: Haring, Martijn P D, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription
por: Salerno, Debora, et al.
Publicado: (2020)

Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma
por: Buchanan, Rebecca A., et al.
Publicado: (2019)

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
por: Scarzello, Anthony J, et al.
Publicado: (2016)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
por: Xiong, Zhewen, et al.
Publicado: (2023)

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
por: Zhang, Tian-Ying, et al.
Publicado: (2020)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
por: Li, Jiang, et al.
Publicado: (2022)

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
por: Conche, Claire, et al.
Publicado: (2023)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Prolonged dual hypothermic oxygenated machine preservation (DHOPE-PRO) in liver transplantation: study protocol for a stage 2, prospective, dual-arm, safety and feasibility clinical trial
por: Brüggenwirth, Isabel M A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_as6hdkf91o2mhpaijpdi6o0rs3